IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
IN8bio, Inc. (INAB)
Company Research
Source: GlobeNewswire
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“?d”) T cell engager through an Investigational New Drug (“IND”) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of 2027 NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (“IN8Bio” or the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative ?d T cell therapies for cancer and autoimmune diseases, today announced that it has entered into a definitive securities purchase agreement (“SPA”) with certain institutional and accredited investors for up to approximately $40.2 million in gross proceeds through a private placement, priced at-the-market under Nasdaq rules. The net proceeds from the initial tranche of the financing are expected to fund the Company’s current operating plans into the first half of
Show less
Read more
Impact Snapshot
Event Time:
INAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INAB alerts
High impacting IN8bio, Inc. news events
Weekly update
A roundup of the hottest topics
INAB
News
- IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager [Yahoo! Finance]Yahoo! Finance
- IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- IN8bio Reports Third Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewswire
- IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New SiteGlobeNewswire
- IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune IndicationsGlobeNewswire
INAB
Earnings
- 5/7/25 - Miss
INAB
Sec Filings
- 11/24/25 - Form 8-K
- 11/7/25 - Form S-3
- 11/6/25 - Form 10-Q
- INAB's page on the SEC website